Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2025 Jun;27(6):2909-2919.
doi: 10.1111/dom.16321. Epub 2025 Apr 2.

Practical considerations for using the Omnipod® 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe

Cari Berget  1 , S Francesca Annan  2 , Torben Biester  3 , Pratik Choudhary  4 , Gregory P Forlenza  1 , Anne L Peters  5 , Eric Renard  6 , Dorothee Deiss  7
Affiliations
Review

Practical considerations for using the Omnipod® 5 Automated Insulin Delivery System: Clinical experience from the United States and Europe

Cari Berget et al. Diabetes Obes Metab. 2025 Jun.

Abstract

Automated insulin delivery (AID) systems, which consist of an insulin pump, a continuous glucose monitoring system and a software algorithm to automate insulin delivery based on real time glycaemic data, are rapidly evolving. AID is now strongly recommended as the insulin delivery method of choice for people with type 1 diabetes. This article reviews the features and current multinational availability of the Omnipod® 5 Automated Insulin Delivery System and summarizes the latest evidence in support of its efficacy, safety and optimal use. It also provides a series of clinical vignettes illustrating advanced issues related to the initiation and ongoing optimization of insulin therapy using the system, including how to personalize settings and optimize glycaemic outcomes in a variety of clinical circumstances.

Keywords: CSII; glycaemic control; hypoglycaemia; insulin pump therapy; insulin therapy; type 1 diabetes.

PubMed Disclaimer

References

REFERENCES

    1. American Diabetes Association Professional Practice Committee. 7. Diabetes technology: standards of Care in Diabetes—2024. Diabetes Care. 2024;47(Suppl. 1):S126‐S144.
    1. Holt RIG, DeVries JH, Hess‐Fischl A, et al. The management of type 1 diabetes in adults: a consensus report by the American Diabetes Association (ADA) and the European Association for the Study of diabetes (EASD). Diabetes Care. 2021;44(11):2589‐2625. doi:10.2337/dci21‐0043
    1. Sherr JL, Schoelwer M, Dos Santos TJ, et al. ISPAD clinical practice consensus guidelines 2022: diabetes technologies: insulin delivery. Pediatr Diabetes. 2022;23(8):1406‐1431. doi:10.1111/pedi.13421
    1. Brown SA, Kovatchev BP, Raghinaru D, et al. Six‐month randomized, multicenter trial of closed‐loop control in type 1 diabetes. N Engl J Med. 2019;381(18):1707‐1717. doi:10.1056/NEJMoa1907863
    1. Bionic Pancreas Research Group, Russell SJ, Beck RW, Damiano ER, et al. Multicenter, randomized trial of a bionic pancreas in type 1 diabetes. N Engl J Med. 2022;387:1161‐1172.

Grants and funding

LinkOut - more resources